Setipafant is primarily used in medical research and clinical applications as a potent antagonist of platelet-activating factor (PAF). It is studied for its potential to mitigate inflammatory responses, particularly in conditions like asthma, sepsis, and other inflammatory disorders. By blocking PAF receptors, it helps reduce symptoms associated with excessive inflammation, such as bronchoconstriction and vascular permeability. Its application in experimental models has provided insights into the role of PAF in various diseases, aiding in the development of targeted therapies. However, its use remains largely confined to research settings, with ongoing studies exploring its therapeutic efficacy and safety in humans.